Estimate | Standard Error | p-value | |
---|---|---|---|
Intercept | 0.820 | 0.071 | < 0.0001 |
Gender (females vs males) | − 0.055 | 0.024 | 0.028 |
Visit (6-month follow up vs baseline) | 0.093 | 0.015 | < .0.0001 |
Visit (12-month follow up vs baseline) | 0.099 | 0.015 | < .0.0001 |
Age (years) | 0.000 | 0.001 | 0.826 |
Comorbidities (no vs yes) | 0.037 | 0.025 | 0.147 |
Smoke (current/former vs no smoker) | − 0.009 | 0.028 | 0.752 |
Asthma duration (years) | 0.000 | 0.001 | 0.712 |
ICS (no vs yes) | − 0.026 | 0.029 | 0.382 |
ICS + LABA (no vs yes) | − 0.032 | 0.041 | 0.439 |
OCS (no vs yes) | 0.039 | 0.036 | 0.278 |
Omalizumab total dose (mg) | 0.000 | 0.003 | 0.510 |
Exacerbations in the 12 months before enrollment (0 vs ≥ 1) | 0.052 | 0.063 | 0.409 |